Neil Kumar Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Neil Kumar.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Neil Kumar. Neil Kumar is Chief Executive Officer in Eidos Therapeutics, Inc. ($EIDX) and CEO and President in BridgeBio Pharma, Inc. ($BBIO) and See Remarks in BridgeBio Pharma, Inc. ($BBIO).
Latest Insider Trading Transactions of Neil Kumar
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Feb 18 2021 | BBIO | BridgeBio Pharma, ... | Kumar Neil | CEO and President | Option Exercise | M | 0.00 | 5,129 | 0 | 66,682 | |
Feb 18 2021 | BBIO | BridgeBio Pharma, ... | Kumar Neil | CEO and President | Payment of Exercise | F | 62.50 | 16,000 | 1,000,000 | 4,711,425 | 4.7 M to 4.7 M (+0.34 %) |
Feb 18 2021 | BBIO | BridgeBio Pharma, ... | Kumar Neil | CEO and President | Payment of Exercise | F | 64.98 | 2,139 | 138,992 | 4,695,425 | 4.7 M to 4.7 M (-0.05 %) |
Feb 18 2021 | BBIO | BridgeBio Pharma, ... | Kumar Neil | CEO and President | Buy | M | 0.00 | 5,129 | 0 | 4,697,564 | 4.7 M to 4.7 M (+0.11 %) |
Feb 12 2021 | BBIO | BridgeBio Pharma, ... | Kumar Neil | CEO and President | Option Exercise | A | 0.00 | 38,306 | 0 | 38,306 | |
Feb 12 2021 | BBIO | BridgeBio Pharma, ... | Kumar Neil | CEO and President | Option Exercise | A | 68.87 | 225,971 | 15,562,623 | 225,971 | |
Nov 18 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | CEO and President | Option Exercise | M | 0.00 | 5,129 | 0 | 71,811 | |
Nov 18 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | CEO and President | Payment of Exercise | F | 44.33 | 1,774 | 78,641 | 4,692,435 | 4.7 M to 4.7 M (-0.04 %) |
Nov 18 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | CEO and President | Buy | M | 0.00 | 5,129 | 0 | 4,694,209 | 4.7 M to 4.7 M (+0.11 %) |
Aug 18 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | CEO and President | Option Exercise | M | 0.00 | 5,129 | 0 | 76,940 | |
Aug 18 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | CEO and President | Payment of Exercise | F | 28.53 | 1,774 | 50,612 | 4,689,080 | 4.7 M to 4.7 M (-0.04 %) |
Aug 18 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | CEO and President | Buy | M | 0.00 | 5,129 | 0 | 4,690,854 | 4.7 M to 4.7 M (+0.11 %) |
Aug 05 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | CEO and President | Sell | S | 27.36 | 6,759 | 184,914 | 2,085,372 | 2.1 M to 2.1 M (-0.32 %) |
Aug 05 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | CEO and President | Sell | S | 26.70 | 7,184 | 191,846 | 2,092,131 | 2.1 M to 2.1 M (-0.34 %) |
Aug 05 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | CEO and President | Sell | S | 28.12 | 3,040 | 85,498 | 2,099,315 | 2.1 M to 2.1 M (-0.14 %) |
Aug 05 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | CEO and President | Sell | S | 27.23 | 63,017 | 1,715,808 | 2,102,355 | 2.2 M to 2.1 M (-2.91 %) |
Jul 06 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | CEO and President | Sell | S | 30.22 | 56,445 | 1,706,022 | 2,165,372 | 2.2 M to 2.2 M (-2.54 %) |
Jul 06 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | CEO and President | Sell | S | 32.42 | 2,700 | 87,521 | 2,221,817 | 2.2 M to 2.2 M (-0.12 %) |
Jul 06 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | CEO and President | Sell | S | 31.67 | 33,700 | 1,067,343 | 2,224,517 | 2.3 M to 2.2 M (-1.49 %) |
Jul 06 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | CEO and President | Sell | S | 30.63 | 50,625 | 1,550,472 | 2,258,217 | 2.3 M to 2.3 M (-2.19 %) |
Jun 10 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | CEO and President | Sell | S | 30.01 | 10,600 | 318,125 | 2,308,842 | 2.3 M to 2.3 M (-0.46 %) |
Jun 05 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | CEO and President | Option Exercise | A | 0.00 | 82,069 | 0 | 82,069 | |
Jun 05 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | CEO and President | Option Exercise | A | 28.86 | 590,551 | 17,043,302 | 590,551 | |
Jun 05 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | CEO and President | Sell | S | 30.05 | 5,930 | 178,173 | 2,319,442 | 2.3 M to 2.3 M (-0.26 %) |
Jun 03 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | CEO and President | Sell | S | 29.71 | 8,709 | 258,711 | 2,325,372 | 2.3 M to 2.3 M (-0.37 %) |
Jun 03 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | CEO and President | Sell | S | 29.13 | 71,291 | 2,076,678 | 2,334,081 | 2.4 M to 2.3 M (-2.96 %) |
May 06 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | CEO and President | Sell | S | 31.23 | 34,834 | 1,088,012 | 2,405,372 | 2.4 M to 2.4 M (-1.43 %) |
May 06 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | CEO and President | Sell | S | 30.86 | 44,766 | 1,381,470 | 2,440,206 | 2.5 M to 2.4 M (-1.80 %) |
Apr 09 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | CEO and President | Sell | S | 25.48 | 1,805 | 45,983 | 2,565,372 | 2.6 M to 2.6 M (-0.07 %) |
Apr 06 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | CEO and President | Sell | S | 25.10 | 100 | 2,510 | 2,567,177 | 2.6 M to 2.6 M (0.00 %) |
Apr 06 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | CEO and President | Sell | S | 25.09 | 200 | 5,018 | 2,567,277 | 2.6 M to 2.6 M (-0.01 %) |
Apr 03 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | CEO and President | Sell | S | 25.04 | 15,778 | 395,103 | 2,567,477 | 2.6 M to 2.6 M (-0.61 %) |
Apr 03 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | CEO and President | Sell | S | 28.20 | 1,382 | 38,979 | 2,583,255 | 2.6 M to 2.6 M (-0.05 %) |
Apr 03 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | CEO and President | Sell | S | 27.45 | 12,976 | 356,252 | 2,584,637 | 2.6 M to 2.6 M (-0.50 %) |
Apr 03 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | CEO and President | Sell | S | 26.38 | 20,040 | 528,623 | 2,597,613 | 2.6 M to 2.6 M (-0.77 %) |
Apr 03 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | CEO and President | Sell | S | 25.52 | 27,719 | 707,508 | 2,617,653 | 2.6 M to 2.6 M (-1.05 %) |
Feb 07 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | CEO and President | Sell | S | 34.87 | 30,893 | 1,077,390 | 2,765,372 | 2.8 M to 2.8 M (-1.10 %) |
Feb 05 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | See Remarks | Sell | S | 34.55 | 54,951 | 1,898,387 | 2,796,265 | 2.9 M to 2.8 M (-1.93 %) |
Feb 05 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | See Remarks | Sell | S | 35.20 | 2,100 | 73,914 | 2,851,216 | 2.9 M to 2.9 M (-0.07 %) |
Feb 05 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | See Remarks | Sell | S | 34.92 | 32,056 | 1,119,309 | 2,853,316 | 2.9 M to 2.9 M (-1.11 %) |
Jan 06 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | See Remarks | Sell | S | 32.88 | 6,668 | 219,250 | 2,885,372 | 2.9 M to 2.9 M (-0.23 %) |
Jan 06 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | See Remarks | Sell | S | 32.14 | 77,271 | 2,483,706 | 2,892,040 | 3 M to 2.9 M (-2.60 %) |
Jan 06 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | See Remarks | Sell | S | 35.17 | 100 | 3,517 | 2,969,311 | 3 M to 3 M (0.00 %) |
Jan 06 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | See Remarks | Sell | S | 34.19 | 5,077 | 173,560 | 2,969,411 | 3 M to 3 M (-0.17 %) |
Jan 06 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | See Remarks | Sell | S | 33.41 | 19,793 | 661,342 | 2,974,488 | 3 M to 3 M (-0.66 %) |
Jan 06 2020 | BBIO | BridgeBio Pharma, ... | Kumar Neil | See Remarks | Sell | S | 32.55 | 11,091 | 361,042 | 2,994,281 | 3 M to 3 M (-0.37 %) |
Jul 08 2019 | EIDX | Eidos Therapeutics ... | Kumar Neil | Chief Executive Off ... | Buy | P | 29.90 | 882,353 | 26,382,796 | 24,575,501 | 23.7 M to 24.6 M (+3.72 %) |
Jul 08 2019 | EIDX | Eidos Therapeutics ... | Kumar Neil | Chief Executive Off ... | Buy | P | 29.90 | 882,353 | 26,382,796 | 24,575,501 | 23.7 M to 24.6 M (+3.72 %) |
Jul 03 2019 | BBIO | BridgeBio Pharma, ... | Kumar Neil | See Remarks | Option Exercise | M | 0.00 | 1,907,102 | 0 | 0 | |
Jul 03 2019 | BBIO | BridgeBio Pharma, ... | Kumar Neil | See Remarks | Option Exercise | M | 0.00 | 2,744,459 | 0 | 0 | |
Jul 03 2019 | BBIO | BridgeBio Pharma, ... | Kumar Neil | See Remarks | Option Exercise | M | 0.00 | 927,686 | 0 | 0 | |
Jul 03 2019 | BBIO | BridgeBio Pharma, ... | Kumar Neil | See Remarks | Option Exercise | M | 0.00 | 1,742,631 | 0 | 0 | |
Jul 03 2019 | BBIO | BridgeBio Pharma, ... | Kumar Neil | See Remarks | Option Exercise | M | 0.00 | 400,375 | 0 | 0 | |
Jul 03 2019 | BBIO | BridgeBio Pharma, ... | Kumar Neil | See Remarks | Option Exercise | M | 0.00 | 906,905 | 0 | 0 | |
Jul 03 2019 | BBIO | BridgeBio Pharma, ... | Kumar Neil | See Remarks | Option Exercise | M | 0.00 | 323,270 | 0 | 0 | |
Jul 03 2019 | BBIO | BridgeBio Pharma, ... | Kumar Neil | See Remarks | Buy | M | 0.00 | 927,686 | 0 | 927,686 | 0 to 927.7 K |
Jul 03 2019 | BBIO | BridgeBio Pharma, ... | Kumar Neil | See Remarks | Buy | M | 0.00 | 400,375 | 0 | 400,375 | 0 to 400.4 K |
Jul 03 2019 | BBIO | BridgeBio Pharma, ... | Kumar Neil | See Remarks | Buy | M | 0.00 | 1,907,102 | 0 | 7,624,367 | 5.7 M to 7.6 M (+33.36 %) |
Jul 03 2019 | BBIO | BridgeBio Pharma, ... | Kumar Neil | See Remarks | Buy | M | 0.00 | 2,744,459 | 0 | 5,717,265 | 3 M to 5.7 M (+92.32 %) |
Jul 03 2019 | BBIO | BridgeBio Pharma, ... | Kumar Neil | See Remarks | Buy | M | 0.00 | 1,742,631 | 0 | 2,972,806 | 1.2 M to 3 M (+141.66 %) |
Jul 03 2019 | BBIO | BridgeBio Pharma, ... | Kumar Neil | See Remarks | Buy | M | 0.00 | 906,905 | 0 | 1,230,175 | 323.3 K to 1.2 M (+280.54 %) |
Jul 03 2019 | BBIO | BridgeBio Pharma, ... | Kumar Neil | See Remarks | Buy | M | 0.00 | 323,270 | 0 | 323,270 | 0 to 323.3 K |
May 29 2019 | EIDX | Eidos Therapeutics ... | Kumar Neil | Chief Executive Off ... | Buy | P | 25.93 | 1,103,848 | 28,622,779 | 23,693,148 | 22.6 M to 23.7 M (+4.89 %) |
Jun 22 2018 | EIDX | Eidos Therapeutics ... | Kumar Neil | Chief Executive Off ... | Option Exercise | C | 0.00 | 12,832,123 | 0 | 0 | |
Jun 22 2018 | EIDX | Eidos Therapeutics ... | Kumar Neil | Chief Executive Off ... | Option Exercise | C | 0.00 | 2,909,029 | 0 | 0 | |
Jun 22 2018 | EIDX | Eidos Therapeutics ... | Kumar Neil | Chief Executive Off ... | Option Exercise | X | 0.00 | 332,262 | 0 | 2,909,029 | |
Jun 22 2018 | EIDX | Eidos Therapeutics ... | Kumar Neil | Chief Executive Off ... | Option Exercise | X | 10.83 | 332,262 | 3,599,992 | 0 | |
Jun 22 2018 | EIDX | Eidos Therapeutics ... | Kumar Neil | Chief Executive Off ... | Buy | P | 17.00 | 1,000,000 | 17,000,000 | 19,614,655 | 18.6 M to 19.6 M (+5.37 %) |
Jun 22 2018 | EIDX | Eidos Therapeutics ... | Kumar Neil | Chief Executive Off ... | Payment of Exercise | F | 17.00 | 211,762 | 3,599,954 | 18,614,655 | 18.8 M to 18.6 M (-1.12 %) |
Jun 22 2018 | EIDX | Eidos Therapeutics ... | Kumar Neil | Chief Executive Off ... | Buy | C | 0.00 | 18,826,417 | 0 | 18,826,417 | 0 to 18.8 M |
Page: 1